← All Tevogen Bio Holdings INC filings

Tevogen Bio Holdings INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TVGN
Tevogen Bio Holdings INC
10-K/A: Tevogen Bio Files 10-K/A for Proxy Disclosure
Tevogen Bio Holdings Inc. filed an amendment to its 2025 Annual Report to include required Part III information previously omitted from the original filing.
NASDAQ
TVGN
Tevogen Bio Holdings INC
10-K: Tevogen Bio Reports 2025 Annual Results, Advances Cell Therapy Pipeline
Tevogen Bio Holdings Inc. reported a net loss of $26.3 million for 2025, alongside positive Phase 1 clinical trial results for TVGN 489 and ongoing development of its ExacTcell technology.
NASDAQ
TVGN
Tevogen Bio Holdings INC
10-K: Tevogen Bio Holdings Inc. Outlines Financials, Strategy in Annual 10-K Filing
Tevogen Bio Holdings Inc. details its financial standing, development strategy, and regulatory landscape in its annual 10-K filing, emphasizing its ExacTcell technology and lead product candidate, TVGN 489.
NASDAQ
TVGN
Tevogen Bio Holdings INC
10-K: Tevogen Bio Holdings Inc. Details Securities and Corporate Structure in 10-K Filing
Tevogen Bio Holdings Inc. outlines the terms of its common and preferred stock, warrants, and various corporate governance provisions in its latest 10-K filing.